secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001178913-25-003005
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics 2024 net loss $16.5M, auditor flags going concern doubt
-----------------------------------------------------------------------------

- Net loss of $16.5M in 2024 vs $5.1M in 2023; operating expenses $12.6M.
- Cash used in operations $8.4M; cash and equivalents $1.2M at Dec 31, 2024.
- Auditor emphasizes substantial doubt about going concern due to recurring losses.
- Total liabilities $6.9M exceed assets $2.9M; capital deficiency of $4.0M.
- Financial statements retroactively adjusted for 1-for-15 reverse split effective July 28, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003005/0001178913-25-003005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003005/zk2533676.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer